Effect of whey protein supplementation combined with resistance training on cellular health in pre-conditioned older women: A randomized,double-blind,placebo-controlled trial

AimThe purpose of study was to analyze the effects of a combined whey protein (WP) and RT intervention on cellular health in pre-conditioned older women.MethodsThe protocol is a randomized controlled clinical trial with a sample of seventy older women, divided into 3 groups: WP-placebo (WP-PLA, n = 24), placebo-WP (PLA-WP, n = 23), and placebo-placebo (PLA-PLA, n = 23). Each group drank 35 g of product (placebo or WP) pre- and post- training. The RT program was carried out over 12 weeks (3x/week; 3 × 8–12 repetitions maximum). Total body water (TBW), intra (ICW) and extracellular (ECW) water, resistance (R), reactance (Xc), and phase angle (PhA) assessed by bioimpedance spectroscopy. Lean soft tissue (LST) was measured using dual energy X-ray absorptiometry; and food consumption was assessed by means of the average of two 24-hour recalls. ANCOVA for repeated measures was applied for comparisons, with baseline scores used as covariates.ResultsA group by time interaction (P < 0.05) was observed for LST, ICW and the ECW/ICW ratio. There was a time effect (P < 0.05) for TBW, Xc, and PhA. A reduction (P <0.05) in R was found only in the WP-PLA and PLA-WP groups.ConclusionWhey protein supplementation (pre- or post-) combined with RT promoted an increase in ICW and LST, and also a reduction in ECW/ICW ratio in pre-conditioned older women. Regardless of the supplementation intake, the RT regimen improved PhA in older adult women. This trial was registered at ClinicalTrials.gov: NCT03247192.     

Serum uric acid level and bone mineral density in Iraqi postmenopausal women

BackgroundThe role of uric acid (UA) in bone mineral density (BMD) has been investigated with diverse results.Aim of the workTo study the relation between serum UA and BMD in Iraqi postmenapausal women.Patients and methodsThe study involved 151 Iraqi postmenapausal women recruited from Baghdad Medical City. Serum UA was measured on two occasions and subjects were categorized into four quartiles according to the serum concentrations. BMD was measured by dual energy x-ray absorptiometry (DXA) and T-score calculated at the lumbar spine (L1-L4) and right femoral neck.ResultsThe mean age of the subjects was 53 ± 9.1 years, body mass index was 31 ± 3.68 and the menopause duration was 8.13 ± 5.86 years. Their mean serum UA level was 4.72 ± 1.35 mg/dl. 56 (37.1%) subjects were osteopenic and 34 (22.5%) were osteoporotic. The mean BMD increased significantly across the quartiles; the highest was in the fourth UA quartile (highest) for both the lumbar spine and right femoral neck. The percentage of women with osteoporosis and osteopenia were lowest in the fourth UA quartile. UA was significantly associated with BMD at L1-L4 spine (p = 0.04) and right femoral neck (p = 0.004) and with the corresponding T-scores (p = 0.008 and p = 0.01 respectively). After adjusting for confounding factors for UA on BMD, only the association of UA with L1-L4 BMD (β = 0.03, p = 0.01) and T-value (β = 0.32, p = 0.009) was still significant.ConclusionHigher serum UA levels were associated with higher BMDs at the lumbar spine suggesting that it may have a beneficial effect on the bone density.     

Haemoglobin levels are associated with bone mineral density in the elderly: a population-based study

Hypoxemia has been associated with low bone mineral density (BMD) in animal and human models. We assessed the association of haemoglobin levels with ultrasound-derived (UD) T score, Z score and the stiffness index in all 358 subjects aged 75+ living in Tuscania (Italy). Also, we searched for the haemoglobin cutoff levels that might best identify participants with osteoporosis. In the multivariable linear regression analysis, haemoglobin levels were associated among participants with the UD T score [β = 0.13; 95% confidence interval (CI) = 0.01–0.25; p = 0.030], Z score (β = 0.11; 95% CI = 0.01–0.22; p = 0.045) and stiffness index (β = 1.87; 95% CI = 0.51–3.21; p = 0.007) after adjusting for potential confounders. Haemoglobin levels <140 g/L in men and <130 g/L in women best predicted osteoporosis in linear discriminant analysis. Haemoglobin is independently associated with all UD-BMD parameters. Haemoglobin levels <140 g/L in men and 130 g/L in women might be adopted in clinical practice to identify older subjects in whom screening for osteoporosis might yield higher effectiveness.     

Appendicular skeletal muscle mass is the strongest independent factor associated with femoral neck bone mineral density in adult and older men

The relationship between bone mass and muscle mass may be due to the site-specific effects of loading on bone in adults and to lifestyle, nutritional, and hormonal factors. Another hypothesis is that the maintenance with aging of both appendicular muscle and bone mass may be determined by factors independent of all these previous factors, including genetic factors. In 160 healthy men aged 20 to 72 years, we recorded femoral neck bone mineral density (FN BMD), relative appendicular skeletal muscle mass [RASM; appendicular skeletal muscle mass (kg) / height (cm)], age, body mass, maximum grip and knee extension strength, lifetime physical activities, calcium intake, tobacco smoking, and serum parathyroid hormone (PTH), estradiol (E2), free testosterone, dehydroepiandrosterone sulphate (DHEAS), insulin-like growth factor (IGF-I), sex hormone-binding globulin (SHBG), calcium, 25(OH) vitamin D, albumin, and creatinine clearance. The correlation between FN BMD and RASM (that includes upper and lower limb muscle mass) was of slightly greater magnitude than that between FN BMD and the relative upper limb muscle mass and between FN BMD and the relative leg muscle mass (r = 0.39; p ≤ 0.001 versus r = 0.36; p ≤ 0.001 and r = 0.34; p ≤ 0.001, respectively). The stepwise multiple linear regression model showed that FN BMD was significantly associated with RASM (15% of FN BMD variance, p < 0.0001), age (10% of FN BMD variance, p < 0.0001), physical activities from age 11–20 years (5% of FN BMD variance, p < 0.01), and blood PTH, IGF-I, and creatinine clearance, (2%, 2%, and 1% of FN BMD variance, respectively, p < 0.05). These results show that RASM, with ASM measured by DXA, is the strongest factor associated with FN BMD in men. It remains to be determined whether assessing RASM by anthropometric methods would help screening adult men at risk of low FN BMD. Furthermore, since RASM is associated with FN BMD independently of appendicular skeletal loads and other lifestyle, nutritional, and hormonal factors, this suggests that common factors, possibly genetic factors, might also influence the coupled maintenance of appendicular muscle mass and FN BMD in adult men.     

老年男性骨代谢相关性激素与年龄和骨密度的相关性

目的探讨老年男性的性激素水平,包括血清睾酮（TTT）、雌二醇（E2）、脱氢表雄酮硫酸酯（DHEAS）随年龄的变化及与多部位骨密度（BMD）之间的关系。方法采用化学发光法测定108例55～92岁男性血清TTT、E2,ELISA法测定血清DHEAS、DEXA测定腰椎正位、股骨颈、大转子、大转子内侧、髋部和Ward＇s三角（Ward＇s）的BMD。根据年龄和BMD诊断标准技血清E2水平的四分位间距分组,年龄分组按每10岁年龄段分为5组,按BMI分为正常组、超重组和肥胖组3组,按T值＞-1．0 s、-2．5 s～-1．0s及≤-2．5 s分为正常骨量组、低骨量组及骨质疏松组,比较各组性激素的差异和BMD的关系。结果（1）各年龄组血清DHEAS水平随增龄而降低（P＜0．05）,与年龄呈负相关（r=-0．596,P＜0．01）,血清E2!、TTT水平与增龄无相关性。（2）正常骨量组、低骨量组、骨质疏松组血清E_1水平逐渐降低（P＜0．05）;股骨上端和腰椎BMD与E2呈正相关（r分别为0．247～0．366,P＜0．05）,与血清TTT和DHEAS水平无相关性,经校正年龄。体质量和BMI后,偏相关分析仍示与血清E1水平相关（r=0．256～0．322,P＜20．05）。各部位的BMD在E2的第1和第2分位间距差异有统计学意义（P＜0．05）,第3和第4分位间距差异无统计学意义。结论（1）老年男性血清DHEAS水平与年龄呈负相关,随增龄而降低;（2）血清E2水平是影响老年男性骨量的一个独立危险因素,动态监测可用于预测老年男性的骨量丢失。     

Decreased bone mineral density in adult familial Mediterranean fever patients: a pilot study

We investigated the association between familial Mediterranean fever (FMF) and osteoporosis (OP) in adult patients. Thirty-five attack-free FMF patients (28 females, 7 males; mean age 36.9 +/- 5.7 years) were individually matched to control subjects on the basis of age (within 2 years) and sex. All patients were taking regular colchicine. Subjects having any condition that can cause decreased bone mineral density (BMD) were excluded from the study. BMD was measured at the spine and femur by dual X-ray absorptiometry (DXA). Data was given as the median (IQR). T scores of the spine were -0.700 (-1.097 to -0.262) and -0.450 (-0.830 to 0.112) in FMF patients and healthy controls, respectively (p > 0.05). T scores of the femur neck were -0.900 (-1.480 to -0.570) and -0.430 (-1.472 to 0.247) in FMF patients and healthy controls, respectively (p > 0.05). Total femur T scores were significantly lower in FMF patients than healthy controls (-0.780 [-1.222 to -0.085] vs. -0.100 [-0.765 to 0.537], respectively, p = 0.021). Total femur T scores were significantly decreased in adult patients with FMF. Ongoing subclinical inflammation may be associated with decreased bone mineral content in those patients.     

Total and regional bone mineral content in normal premenopausal women

Summary In the present, cross-section study, a total of 185 normal premenopausal females—aged 15 through 19 years (n=40), 20 to 29 years (n=60), 30 through 39 years (n=40) and 40 to 49 years (n=45)- were assessed in order to observe and evaluate the total body bone mineral content and the regional body mineral content of different anatomical regions (head, trunk, arms and legs), when the bone mass peak is established in women and its course during premenopause. All subjects underwent bone densitometry with dual energy X-ray absorptiometry with a Norland XR-26 bone densitometer. No differences between groups were found in total body bone mineral and regional bone mineral content values. Total body bone mineral values (mean±SD) were 2546±461 g and 2691±499 g in the 15–19 year-old group and 40–49 year-old group respectively. The regional bone mineral content values for the same age group were 495±75 g and 499±89 g for the head, 1007±254 g and 1043±212 g for the trunk, 327±74 g and 336±81 for the arms, and 860±167 g and 811±146 g for the legs. The results of this study indicate that the peak bone mass is reached at the age of 20 years and that it remains stable in the premenopausal eugonadal females.     

老年男性骨密度与钙调节激素测定

目的　探讨钙调节激素在老年男性骨质疏松症发病机制中的作用。　 方法 　 6 3例老年男性分为骨质疏松组与非骨质疏松组 ,测定骨密度 (BMD)、血清钙 (Ca)、磷 (P)、碱性磷酸酶 (AKP)、甲状旁腺激素 (PTH)、降钙素 (CT)、2 5羟维生素D[2 5 (OH) VitD] ,并与 37例青年男性对照。　 结果　老年男性BMD、CT、2 5 (OH) VitD均较对照组降低、PTH增高 (P <0 0 0 1)。骨质疏松组CT、2 5 (OH) VitD较非骨质疏松组降低、PTH增高 (P <0 0 1～ 0 0 0 1)。Ca、P、AKP无明显差异。　 结论 　增龄、钙调节激素异常是引致老年男性骨质疏松症的重要原因之一。     

Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus

The primary objective of this study was to determine the relationship between dietary calcium intake and bone mineral density (BMD) in premenopausal women with systemic lupus erythematosus (SLE) on corticosteroids (CS). The secondary aim was to identify other risk factors for osteoporosis in these patients. A cross-sectional sample of patients attending the SLE Clinic at a teaching hospital was recruited. BMD was measured using dual-energy X-ray absorptiometry. Daily dietary calcium intake was assessed using a structured validated food frequency questionnaire, in which patients were asked to estimate their food intake based on their recent 2-month dietary habits. Sixty subjects were recruited with a mean age of 33.70±8.46 years. The median duration of CS use was 5.5 years (range 0.08–24). The median cumulative dose of steroids was 17.21 g (range 0.16–91.37). The median daily dietary calcium intake was 483 mg (range 78–2101). There was no significant correlation between calcium intake and BMD, even after correcting for CS use. There were also no correlations between BMD and the duration of SLE, cumulative CS use, duration of CS use, smoking, alcohol intake, and SLE disease activity index score. Twenty-eight (46.7%) patients had normal BMD, 28 (46.7%) had osteopenia, and four (6.6%) had osteoporosis. Duration of SLE significantly correlated with cumulative CS dosage. In conclusion, 6.7% of these Asian premenopausal SLE women had osteoporosis and only 46.7% had normal BMD. Daily dietary calcium intake did not correlate with BMD.     

绝经妇女桡骨骨密度变化的多因素分析

目的探讨绝经后骨量丢失的主要危险因素。方法对１５７例绝经后妇女的桡骨骨矿含量与年龄、绝经年龄、身高、体重分别进行简单相关分析和多元线性回归分析。结果桡骨骨矿含量与年龄呈非常显著的负相关（Ｐ＜０．００１），与绝经年龄呈非常显著的正相关（Ｐ＜０．００１），与身高呈显著的正相关（Ｐ＜０．０１），与体重呈显著的正相关（Ｐ＜０．０５）；多元回归中偏回归系数的偏相关系数绝对值的大小依次为：绝经年龄、年龄、身高、体重。结论早绝经是绝经后骨量丢失的主要危险因素     

阿伦膦酸盐联合钙尔奇D对老年女性2型糖尿病骨质疏松患者骨密度的影响

目的 探讨应用阿伦膦酸盐联合钙尔奇D治疗对老年女性2型糖尿病患者不同部位骨质疏松的疗效.方法 选择老年女性2型糖尿病骨质疏松患者34例,年龄60～79岁,平均(68.0±4.5)岁,体质指数(25.0±3.7)kg/cm2,糖尿病病程(8.9±4.4)年.综合治疗基础上,应用阿伦膦酸盐联合钙尔奇D治疗6个月;检测治疗前、后腰椎、髋骨骨密度及血生化指标.结果 治疗后6个月,患者各部位骨密度均增加,腰椎的T值及骨密度均高于髋骨(均P＜0.01).总体上各个部位间T值及骨密度改善差异均有统计学意义(分别为P=0.003和0.005).腰椎骨密度改善百分比:L4(44.7%)＞L3(31.9%)＞L总(27.3%)＞L1(20.0%)＞L2(14.3%),其中L3和L4的骨密度改善百分比显著高于其他腰椎部位(P=0.038,0.008).L3、L总、L1和L4 T值及骨密度改善显著高于L2(T值:P值分别为0.036、0.042、0.006和0.004,骨密度:P值分别为0.002、0.002、0.003和0.001).结论 阿伦膦酸盐联合钙尔奇D治疗老年女性2型糖尿病骨质疏松,短期疗效以腰椎下位椎骨较好,髋骨疗效欠佳.     

Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis

The aim of this study was to evaluate the total antioxidant status (TAS), total oxidative status (TOS) and oxidative stress index (OSI) in patients with postmenopausal osteoporosis. We also investigate the relation between bone mineral density and oxidative/antioxidative parameters. Thirty-nine patients with osteoporosis and 26 healthy controls were included in the study. Plasma TAS, TOS levels were determined by using a novel automated methods. Plasma TOS and OSI value were significantly higher, and plasma TAS level was lower in patients than in healthy controls (P < 0.001 for all). There was a significant negative correlation between OSI and BMD in lumbar and femoral neck region (r = −0.63, P < 0.001; r = 0.40, P = 0.018). The results of this study indicated that increased osteoclastic activity and decreased osteoblastic activity may be associated with an imbalance between oxidant and antioxidant status in postmenopausal osteoporosis. Therefore, supplementation of antioxidant-enriched diet to the therapy might shed light on the development of novel therapeutic strategies for osteoporosis.     

Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women

OBJECTIVE: Hyperthyroidism is accompanied by low bone mass. Because the reference range of TSH levels is defined statistically, some individuals with low normal TSH levels may have mild hyperthyroidism and reduced bone mass. We therefore determined whether serum TSH levels correlate with bone mineral density (BMD). DESIGN: A cross-sectional hospital-based survey. Participants Nine hundred and fifty-nine healthy postmenopausal women. MEASUREMENTS: We measured BMD at the lumbar spine and femoral neck using dual energy X-ray absorptiometry, and serum TSH concentrations using immunoluminometry. RESULTS: BMD at the lumbar spine and femoral neck increased with TSH level (P for trend < 0.001 at both sites). Even after adjustment for age, years since menopause and body mass index, subjects with low normal TSH levels (0.5-1.1 mU/l) had significantly lower BMDs at the lumbar spine (0.863 +/- 0.009 g/cm2 vs 0.900 +/- 0.009 g/cm2, P = 0.004) and femoral neck (0.660 +/- 0.006 g/cm2 vs 0.683 +/- 0.006 g/cm2, P = 0.006) than those with high normal TSH levels (2.8-5.0 mU/l), as well as a 2.2-fold increased risk of osteoporosis (95% confidence interval: 1.2-4.0). CONCLUSION: These results suggest that low normal TSH levels may not be physiological for postmenopausal women and, during treatment of hypothyroidism, may not be adequate for avoiding osteoporosis.     

非胰岛素依赖型糖尿病患者骨密度变化及其主要相关因素分析

目的 研究ＮＩＤＤＭ患者骨密度的变化规律和临床特点。方法 使用双能Ｘ线吸收仪（ＤＥＸＡ）测定４８例非胰岛素依赖型糖尿病（ＮＩＤＤＭ）患者腰２￣４椎体正侧位和髋关节部位的骨密度,并与同性别３０￣３５岁对比,研究其骨密度的变化规律和临床特点。结果 ４８例中有２５例合并有骨质疏松,女性患者的骨密度下降程度明显高于男性患者;两组患者的髋关节部位骨密度下降程度均明显高于腰椎部位。结论 骨密度值与糖尿病病程、     

Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women

CONTEXT: A major determinant of osteoporotic fractures is peak bone mineral density (BMD), which is a highly heritable trait. Recently, we identified significant linkage for hip BMD in premenopausal sister pairs at chromosome 14q (LOD score = 3.5), where the estrogen receptor beta gene (ESR2) is located. OBJECTIVE: The objective of the study was to determine whether ESR2 polymorphisms are associated with normal BMD variation. DESIGN: This was a population-based genetic association study, using 11 single nucleotide polymorphisms (SNPs) distributed across the ESR2 gene. SETTING: The study was conducted at an academic research laboratory and medical center. PATIENTS AND OTHER PARTICIPANTS: A total of 411 healthy men (aged 18-61 yr) and 1291 healthy premenopausal women (aged 20-50 yr) living in Indiana participated in the study. INTERVENTION(S): There were no interventions. MAIN OUTCOME MEASURE(S): The main outcome measures were SNP genotype distributions and their association with BMD at the femoral neck and lumbar spine. Results: Significant association of spine BMD was found with three SNPs in men and one SNP in women (P < or = 0.05). The conditional linkage analysis using the ESR2 haplotypes showed that the ESR2 gene accounts for, at most, 18% of the original linkage. CONCLUSIONS: ESR2 polymorphisms are significantly associated with bone mass in both men and women. However, the ESR2 gene is not entirely responsible for our original linkage, and an additional gene(s) in chromosome 14q contributes to the determination of BMD.     

Sarcopenia and sarcopenic obesity classifications and cardiometabolic risks in older women

The purpose of this study was to examine the association between sarcopenia and sarcopenic obesity (SO) with cardiometabolic risk factors in postmenopausal women. 149 volunteers (67.17 ± 6.12 years) underwent body composition assessment using dual energy X-ray absorptiometry (DXA) and had analyzed blood samples collected for lipid profile, glucose metabolism and C-reactive protein (CRP). Sarcopenia was defined as an appendicular fat-free mass (AFFM) divided by height squared ≤5.45 kg/m² while SO was classified based on the residuals of a regression. Waist circumference (WC) and arterial blood pressure were also measured. Student's t-tests and correlations were used for analyses. Prevalence of sarcopenia and SO were respectively 16.8 and 21.5%. WC was significantly correlated with all the examined risk factors. AFFM relative to height squared was positively correlated with systolic blood pressure (SBP) and diastolic blood pressure (DBP), CRP, insulinaemia, HOMA score, and those classified as sarcopenic presented lower HOMA score when compared to nonsarcopenic. Regarding SO, although volunteers classified presented significantly higher fat mass (FM) and lower AFFM, it was not observed association with the examined risk factors. These findings support the association between WC and cardiometabolic risk factors in older women. In contrast, the approaches used to define sarcopenia and SO are not associated with cardiometabolic impairments.     

Lipid levels and bone mineral density

Purpose

There has been considerable debate about the potential relationship between the use of statin lipid-lowering drugs and fracture risk; several observational studies suggest a protective effect but no randomized controlled trials have confirmed such a benefit. Because statins are given preferentially to persons with hyperlipidemia, if lipid levels were associated with bone mineral density, this could explain the discrepancy between epidemiological observations and randomized controlled trials. The aim of this study was to examine the relationship between lipid levels and bone mineral density.

Subjects and methods

We included the 13 592 participants in the National Health and Nutritional Examination Survey (NHANES) III who had bone mineral density and lipid levels measured; participants who reported the use of a lipid-lowering therapy were excluded. We examined the unadjusted bone mineral density across quintiles of total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). We then constructed multivariable models, including age, sex, body mass index, and other potential confounders.

Results

In crude analyses, higher total cholesterol and LDL levels were associated with lower bone mineral densities (both P values for trend <.001), whereas higher HDL levels were associated with higher bone mineral densities (P value for trend <.001). However, in fully adjusted models, there was no significant relationship between total cholesterol, LDL, or HDL levels and bone mineral density (all P values for trend >.1).

Conclusions

These results do not support a relationship between lipid levels and bone mineral density.     

炎症性肠病患者骨密度降低的多因素分析

目的评估骨质疏松和(或)骨量减少在炎症性肠病(IBD)患者中的发生率,寻找IBD患者发生严重骨密度下降的主要因素,为临床尽早开展预防性治疗,及时诊断提供证据。方法选择66例IBD患者,其中克罗恩病(CD)38例,溃疡性结肠炎(UC)28例,测定患者骨密度,记录其主要症状,体征及实验室检查结果,制订治疗方案。根据CD活动指数(AI)和Truelove-Witts评分确定病情活动度。结果进行统计学分析。结果62例患者完成研究,平均年龄(40.9±15.4)岁。腰椎部出现骨质疏松和骨量减少者分别为21.0%和29.0%;股骨颈则分别为19.4%和6.5%,腰椎较股骨颈更易发生严重骨密度下降(P= 0.005)。CD患者较UC患者更易发生骨质疏松和(或)骨量减少(P=0.001)。激素用量、体重指数的变化、病变范围、女性绝经和患者T值变化均相关。结论骨量减少与骨质疏松在IBD患者中普遍存在。年龄、激素、体重指数、病变范围、女性绝经和患者T值变化均相关。疾病活动度与骨密度下降是否存在联系尚待明确。     

性激素阻断治疗对前列腺癌患者骨代谢及骨量的影响

目的探讨药物去势方法治疗老年人前列腺癌对患者骨代谢和骨量的影响。方法以确诊的老年前列腺癌患者36例作为观察组（前列腺癌组），无前列腺癌及影响骨代谢疾病的老年男性13例作为对照组。前列腺癌组分别在诺雷德（Goserelin）去势前和去势后12个月测定2～4腰椎、左股骨颈、大转子、Ward’s三角和全髋的骨密度，并检测血中的骨特异性碱性磷酸酶（BALP）、骨钙素（BGP）、甲状旁腺素（PTH）、Ⅰ型前胶原末端肽（CICP）、抗酒石酸酸性磷酸酶（TRACP）及尿吡啶啉（PYD）、脱氧吡啶啉（DPD）、Ⅰ型胶原C端交联物（Cros）、尿钙／尿肌酐比值（Ca／Cr）等骨代谢指标，对照组同期检测上述项目。结果前列腺癌组在Goserelin去势前和对照组相比，骨密度和骨代谢各项指标差异无统计学意义（P〉0．05）；前列腺癌组经过Goserelin 12个月的治疗后，血雄激素和雌激素等性激素水平都显著性降低（P均〈0．01）；血BALP、尿DPD、Cros、Ca／Cr明显增高，全髋、左股骨颈、Ward’s三角3个部位的骨量丢失显著，变化率与对照组比较差异有统计学意义（均为P〈0．05）。结论前列腺癌患者接受Goserelin去势治疗后发生明显的骨转换增加和骨量丢失，与体内雄激素和雌激素水平极度降低有关，故对于这些患者监测骨密度和骨代谢指标有利于早期发现Goserelin去势治疗后发生的骨质疏松，并及时给予治疗。